Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6500
-0.0050 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
0.6590
+0.0090 (1.38%)
After-hours: Dec 5, 2025, 7:59 PM EST
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$250,381
Profits / Employee
-$979,810
Market Cap
89.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 2 days ago - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - GlobeNewsWire
- 5 days ago - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 12 days ago - Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 16 days ago - Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 19 days ago - Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch - GlobeNewsWire